Stocks and Investing Stocks and Investing
Fri, January 26, 2018
Thu, January 25, 2018

Paul Matteis Maintained (ALNY) at Hold with Increased Target to $135 on, Jan 25th, 2018


Published on 2024-10-26 02:11:46 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $132 to $135 on, Jan 25th, 2018.

Paul has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $130 on, Thursday, November 9th, 2017


These are the ratings of the 6 analyists that currently disagree with Paul


  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy on, Thursday, November 9th, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $158 on, Wednesday, November 8th, 2017
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $220 on, Wednesday, November 8th, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $151 on, Friday, November 3rd, 2017
  • Rahul Jasuja of "FBR Capital" Maintained at Strong Buy with Increased Target to $240 on, Thursday, November 2nd, 2017
  • Terence Flynn of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Monday, October 2nd, 2017

Contributing Sources